These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 30055962)
21. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636 [TBL] [Abstract][Full Text] [Related]
22. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status. Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606 [TBL] [Abstract][Full Text] [Related]
23. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600 [TBL] [Abstract][Full Text] [Related]
25. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer. Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983 [TBL] [Abstract][Full Text] [Related]
26. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase. Ji N; Yuan J; Liu J; Tian S Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767 [TBL] [Abstract][Full Text] [Related]
27. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients. Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489 [TBL] [Abstract][Full Text] [Related]
28. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609). Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583 [TBL] [Abstract][Full Text] [Related]
29. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939 [TBL] [Abstract][Full Text] [Related]
30. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034 [TBL] [Abstract][Full Text] [Related]
31. Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy. Al-Salam S; Sudhadevi M; Awwad A; Al Bashir M BMC Cancer; 2019 Feb; 19(1):135. PubMed ID: 30744593 [TBL] [Abstract][Full Text] [Related]
32. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518 [TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use. Iwamoto M; Takei H; Ninomiya J; Asakawa H; Kurita T; Yanagihara K; Iida S; Sakatani T; Ohashi R J Nippon Med Sch; 2021 Nov; 88(5):448-460. PubMed ID: 33692294 [TBL] [Abstract][Full Text] [Related]
34. Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer. Al Amri WS; Allinson LM; Baxter DE; Bell SM; Hanby AM; Jones SJ; Shaaban AM; Stead LF; Verghese ET; Hughes TA Mol Cancer Ther; 2020 Mar; 19(3):945-955. PubMed ID: 31879365 [TBL] [Abstract][Full Text] [Related]
35. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy. Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285 [TBL] [Abstract][Full Text] [Related]
36. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. Luengo-Gil G; García-Martínez E; Chaves-Benito A; Conesa-Zamora P; Navarro-Manzano E; González-Billalabeitia E; García-Garre E; Martínez-Carrasco A; Vicente V; Ayala de la Peña F Cell Oncol (Dordr); 2019 Oct; 42(5):627-644. PubMed ID: 31115881 [TBL] [Abstract][Full Text] [Related]
37. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Imai Y; Ishikawa E; Asada S; Sugimoto Y Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404 [TBL] [Abstract][Full Text] [Related]
38. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients. Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100 [TBL] [Abstract][Full Text] [Related]
39. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553 [TBL] [Abstract][Full Text] [Related]
40. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. Barbie TU; Ma C; Margenthaler JA Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]